409 related articles for article (PubMed ID: 30987226)
1. Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue.
D'Alessio A; Proietti G; Sica G; Scicchitano BM
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 30987226
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma: pathology, molecular mechanisms and markers.
Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
[TBL] [Abstract][Full Text] [Related]
3. Cancer stem cells from peritumoral tissue of glioblastoma multiforme: the possible missing link between tumor development and progression.
Angelucci C; D'Alessio A; Lama G; Binda E; Mangiola A; Vescovi AL; Proietti G; Masuelli L; Bei R; Fazi B; Ciafrè SA; Sica G
Oncotarget; 2018 Jun; 9(46):28116-28130. PubMed ID: 29963265
[TBL] [Abstract][Full Text] [Related]
4. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
5. Evidence of Reelin Signaling in GBM and Its Derived Cancer Stem Cells.
Biamonte F; Sica G; Filippini A; D'Alessio A
Brain Sci; 2021 Jun; 11(6):. PubMed ID: 34205192
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
7. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
8. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
9. ACTC1 as an invasion and prognosis marker in glioma.
Ohtaki S; Wanibuchi M; Kataoka-Sasaki Y; Sasaki M; Oka S; Noshiro S; Akiyama Y; Mikami T; Mikuni N; Kocsis JD; Honmou O
J Neurosurg; 2017 Feb; 126(2):467-475. PubMed ID: 27081897
[TBL] [Abstract][Full Text] [Related]
10. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
11. Molecular Evolution of
Draaisma K; Chatzipli A; Taphoorn M; Kerkhof M; Weyerbrock A; Sanson M; Hoeben A; Lukacova S; Lombardi G; Leenstra S; Hanse M; Fleischeuer R; Watts C; McAbee J; Angelopoulos N; Gorlia T; Golfinopoulos V; Kros JM; Verhaak RGW; Bours V; van den Bent MJ; McDermott U; Robe PA; French PJ
J Clin Oncol; 2020 Jan; 38(1):81-99. PubMed ID: 31743054
[TBL] [Abstract][Full Text] [Related]
12. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
[TBL] [Abstract][Full Text] [Related]
13. Analysis of angiogenesis related factors in glioblastoma, peritumoral tissue and their derived cancer stem cells.
D'Alessio A; Proietti G; Lama G; Biamonte F; Lauriola L; Moscato U; Vescovi A; Mangiola A; Angelucci C; Sica G
Oncotarget; 2016 Nov; 7(48):78541-78556. PubMed ID: 27705944
[TBL] [Abstract][Full Text] [Related]
14. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
15. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature.
Montemurro N
J Neurol Surg A Cent Eur Neurosurg; 2020 Jan; 81(1):64-70. PubMed ID: 31550738
[TBL] [Abstract][Full Text] [Related]
17. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.
Persano L; Rampazzo E; Basso G; Viola G
Biochem Pharmacol; 2013 Mar; 85(5):612-622. PubMed ID: 23063412
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Agnihotri S; Aldape KD; Zadeh G
Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
[TBL] [Abstract][Full Text] [Related]
19. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
